West Pharma (WST) Tops Q3 EPS by 6c, Revenues Beat; Reaffirms FY18 EPS Mid-Point Guidance Above Consensus, Offers FY18 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to West Pharma (WST) Tops Q3 EPS by 6c, Revenues Beat; Reaffirms FY18 EPS Mid-Point Guidance Above Consensus, Offers FY18 Revenue Outlook

West Announces Third-Quarter 2018 Results

October 25, 2018 6:00 AM EDT

EXTON, Pa., Oct. 25, 2018 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2018 and reaffirmed net sales and adjusted-diluted EPS guidance for full-year 2018. 

Executive Summary

Third-quarter 2018 reported net sales of $431.7 million grew 8.4% over the prior-year quarter. At constant currency, organic sales growth was 9.6%. Third-quarter... More